Neuland Laboratories Q1 FY27 earnings call

Neuland Laboratories reported a robust Q1 FY27, with total income reaching INR650.1 crores, a calculated 116.3% increase from INR300.6 crores in Q1 FY26 (though the transcript stated 16.3% growth). EBITDA for the quarter was INR231.1 crores, achieving a strong EBITDA margin of 35.5%. Profit after tax saw a significant jump to INR147.4 crores from INR13.7 crores in the prior year, resulting in an EPS of INR114.9 per share. The company also improved its working capital efficiency, reducing working capital days from 137 at FY26 end to 84 in Q1 FY27.

Commercial CMS projects were the primary drivers of revenue growth, contributing a majority share of the total income. Within the GDS business, products like Ezetimibe, Mirtazapine, Escitalopram, and Aripiprazole performed well. Management noted that commercial CMS growth is currently driven by a handful of molecules (around 3), which are expected to remain active for the next 5-6 years. The company is focused on expanding its portfolio of differentiated products and increasing presence in key markets like Brazil, Japan, South Korea, and Turkey.

The company incurred a cash outflow of INR121.6 crores for capital expenditure in Q1 FY27, primarily for new R&D and peptide facilities. Additionally, INR203 crores in capital investments were approved, with INR196 crores allocated for strategic growth initiatives, including capacity expansion at Unit 1. Over the last 13 quarters, Neuland has approved INR1,460 crores in capex, spending INR870 crores to date. The management emphasized a disciplined approach to capital allocation, balancing growth with prudent working capital management.

Neuland announced a strategic collaboration with Gland Pharma to create a differentiated platform in sterile APIs. This partnership is an asset-light arrangement, combining Neuland's complex API expertise with Gland Pharma's sterile manufacturing capabilities. The company's peptide manufacturing facility is set to be commissioned next month (August 2026), with manufacturing qualification to follow. Management expressed excitement about multiple projects already lined up for this new facility, reinforcing their long-term conviction in the peptide segment.

Management reiterated its aspiration for approximately 20% revenue growth for both FY27 and FY28. The long-term EBITDA margin target remains at 25% plus, acknowledging that current margins are favorable due to product mix and exchange rates. The development pipeline is considered strong and healthy, with new projects, including peptide-related ones, expected to pave the way for larger volumes in the future. The company anticipates development revenue to increase in FY27, with more molecules contributing to commercial revenue from FY28 onwards.

Neuland continues to monitor the evolving geopolitical environment and broader global trade developments, although no material impact on operations or supply chain continuity has been experienced thus far. The inherent uneven nature of the business, with quarterly volatility influenced by regulatory timelines and customer ordering patterns, was highlighted. While a dip in ROCE is possible due to long-term capital deployment, management believes it will be managed within guardrails, and the new peptide facility's FDA audit is not seen as a gating issue.